Shamburg News · 8-K filed Nov 12, 2026, 4:13 PM EST

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

SER · Serina Therapeutics, Inc.

  • Earnings
  • Other event
  • Materiality: high

Serina Therapeutics reported a net loss attributable to common stockholders of $7.9 million, or $(0.31) per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of $4.7 million, or $(0.45) per share, a year earlier. Operating expenses were $8.0 million for the quarter, and cash and cash equivalents totaled $19.4 million as of September 30, 2026. The company also reported that the independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 of its Parkinson's disease registrational study, and that dosing in Cohort 2 has been initiated.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001708599-26-000069.

Written from the filing by Shamburg Markets. Figures are as reported by the company.